Difference between revisions of "Encorafenib (Braftovi)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
m |
||
| Line 3: | Line 3: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | *[[Colon cancer, BRAF-mutated|BRAF-mutated colon cancer]] | ||
*[[Melanoma,_BRAF-mutated|BRAF-mutated melanoma]] | *[[Melanoma,_BRAF-mutated|BRAF-mutated melanoma]] | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*6/27/2018: Initial FDA approval in combination with [[Binimetinib (Mektovi)]] for patients with unresectable or metastatic [[melanoma]] with a [[Biomarkers#BRAF|BRAF]] [[Biomarkers#V600E|V600E]] or [[Biomarkers#V600K|V600K mutation]], as detected by an FDA-approved test. | *6/27/2018: Initial FDA approval in combination with [[Binimetinib (Mektovi)]] for patients with unresectable or metastatic [[melanoma]] with a [[Biomarkers#BRAF|BRAF]] [[Biomarkers#V600E|V600E]] or [[Biomarkers#V600K|V600K mutation]], as detected by an FDA-approved test. | ||
| + | *4/9/2020: Approved in combination with cetuximab for the treatment of adult patients with metastatic [[:Category:Colorectal_cancers|colorectal cancer (CRC)]] with a [[Biomarkers#BRAF|BRAF]] [[Biomarkers#V600E|V600E mutation]], detected by an FDA-approved test, after prior therapy. | ||
==Also known as== | ==Also known as== | ||
| Line 19: | Line 21: | ||
[[Category:BRAF inhibitors]] | [[Category:BRAF inhibitors]] | ||
| + | [[Category:Colon cancer medications]] | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
[[Category:FDA approved in 2018]] | [[Category:FDA approved in 2018]] | ||
Revision as of 23:53, 9 April 2020
General information
Class/mechanism (from NCI Drug Dictionary): An orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway.
Diseases for which it is used
History of changes in FDA indication
- 6/27/2018: Initial FDA approval in combination with Binimetinib (Mektovi) for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
- 4/9/2020: Approved in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, detected by an FDA-approved test, after prior therapy.
Also known as
- Code name: LGX818
- Brand name: Braftovi